The success and ever increasing interest in incretin-based therapies and drugs especially sitagliptin, vildagliptin and exenatide depict their immense importance in improving patient outcomes in T2DM (Nasr and Sadek, 2022). This evidence concerns the gene GCG and type 2 diabetes mellitus.